Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.49 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10211186 | 1.00 | SPHK1 (0.49) | SPHK1HSD11B2BRD4HCRTR2CHRM2 | |
| SCHEMBL16545981 | 1.00 | SPHK1 (0.49) | SPHK1HSD11B2BRD4HCRTR2CHRM2 | |
| SCHEMBL18595256 | 0.92 | SPHK1 (0.47) | SPHK1HSD11B2BRD4HCRTR2CHRM2 | |
| SCHEMBL30699286 | 0.92 | SPHK1 (0.47) | SPHK1HSD11B2BRD4HCRTR2CHRM2 | |
| SCHEMBL17244141 | 0.88 | SPHK1 (0.48) | SPHK1HSD11B2BRD4HCRTR2CHRM2 | |
| SCHEMBL10211309 | 0.88 | SPHK1 (0.51) | SPHK1HSD11B2BRD4HCRTR2CHRM2 | |
| SCHEMBL31362554 | 0.87 | SPHK1 (0.47) | SPHK1HSD11B2BRD4HCRTR2CHRM2 | |
| SCHEMBL15209134 | 0.86 | SPHK1 (0.48) | SPHK1HSD11B2BRD4HCRTR2CHRM2 | |
| SCHEMBL15209132 | 0.86 | SPHK1 (0.48) | SPHK1HSD11B2BRD4HCRTR2CHRM2 | |
| SCHEMBL1068504 | 0.86 | SPHK1 (0.48) | SPHK1HSD11B2BRD4HCRTR2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3042900-B1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORP (JP) | 2020-09-23 | — | — | EP | disclosed |
| US-20170166571-A1 | TREATMENT OF H. PYLORI INFECTIONS USING MTAN INHIBITORS | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) | 2017-06-15 | — | — | US | disclosed |
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| EP-3042900-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | Fujifilm Corporation (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | PRMT7, RBBP7, RER1 | SPHK1 2999/4885HSD11B2 1812/4885BRD4 221/4885 |
| US-20170166571-A1 | TREATMENT OF H. PYLORI INFECTIONS USING MTAN INHIBITORS | MTAP, PNP, UNG | SPHK1 3541/4885HSD11B2 2863/4885BRD4 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.